405 related articles for article (PubMed ID: 27225222)
21. Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling.
Wang J; Kong PF; Wang HY; Song D; Wu WQ; Zhou HC; Weng HY; Li M; Kong X; Meng B; Chen ZK; Chen JJ; Li CY; Shao JY
J Oncol; 2020; 2020():7526204. PubMed ID: 32411243
[TBL] [Abstract][Full Text] [Related]
22. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
Fatai AA; Gamieldien J
BMC Cancer; 2018 Apr; 18(1):377. PubMed ID: 29614978
[TBL] [Abstract][Full Text] [Related]
23. A Potential Prognostic Gene Signature for Predicting Survival for Glioblastoma Patients.
Hou Z; Yang J; Wang H; Liu D; Zhang H
Biomed Res Int; 2019; 2019():9506461. PubMed ID: 31032367
[TBL] [Abstract][Full Text] [Related]
24. Prognostic power of a lipid metabolism gene panel for diffuse gliomas.
Wu F; Zhao Z; Chai RC; Liu YQ; Li GZ; Jiang HY; Jiang T
J Cell Mol Med; 2019 Nov; 23(11):7741-7748. PubMed ID: 31475440
[TBL] [Abstract][Full Text] [Related]
25. Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas.
Wang J; Ma J
J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):240-249. PubMed ID: 30934097
[TBL] [Abstract][Full Text] [Related]
26. A thirteen‑gene set efficiently predicts the prognosis of glioblastoma.
Yang H; Jin L; Sun X
Mol Med Rep; 2019 Mar; 19(3):1613-1621. PubMed ID: 30628650
[TBL] [Abstract][Full Text] [Related]
27. An immune-related lncRNA signature for patients with anaplastic gliomas.
Wang W; Zhao Z; Yang F; Wang H; Wu F; Liang T; Yan X; Li J; Lan Q; Wang J; Zhao J
J Neurooncol; 2018 Jan; 136(2):263-271. PubMed ID: 29170907
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
29. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.
Yin A; Shang Z; Etcheverry A; He Y; Aubry M; Lu N; Liu Y; Mosser J; Lin W; Zhang X; Dong Y
Oncoimmunology; 2021 Mar; 10(1):1902071. PubMed ID: 33854822
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V
J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134
[TBL] [Abstract][Full Text] [Related]
31. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
32. A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma.
Zuo S; Zhang X; Wang L
Sci Rep; 2019 Feb; 9(1):2615. PubMed ID: 30796273
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
34. Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Jin S; Qian Z; Liang T; Liang J; Yang F; Sun L; Li W; Qiu X; Zhang M
World Neurosurg; 2018 Sep; 117():e34-e41. PubMed ID: 29807183
[TBL] [Abstract][Full Text] [Related]
35. Identification of N
Wang W; Li J; Lin F; Guo J; Zhao J
Neurosurg Rev; 2021 Feb; 44(1):463-470. PubMed ID: 31938968
[TBL] [Abstract][Full Text] [Related]
36. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group.
Arimappamagan A; Somasundaram K; Thennarasu K; Peddagangannagari S; Srinivasan H; Shailaja BC; Samuel C; Patric IR; Shukla S; Thota B; Prasanna KV; Pandey P; Balasubramaniam A; Santosh V; Chandramouli BA; Hegde AS; Kondaiah P; Sathyanarayana Rao MR
PLoS One; 2013; 8(4):e62042. PubMed ID: 23646114
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
Li C; Liu F; Sun L; Liu Z; Zeng Y
BMC Cancer; 2022 Mar; 22(1):230. PubMed ID: 35236310
[TBL] [Abstract][Full Text] [Related]
38. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.
Cai J; Zhang W; Yang P; Wang Y; Li M; Zhang C; Wang Z; Hu H; Liu Y; Li Q; Wen J; Sun B; Wang X; Jiang T; Jiang C
PLoS One; 2015; 10(5):e0126022. PubMed ID: 25978454
[TBL] [Abstract][Full Text] [Related]
39. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
40. Decreased BRMS1L expression is correlated with glioma grade and predicts poor survival in glioblastoma via an invasive phenotype.
Lv J; Yang H; Wang X; He R; Ding L; Sun X
Cancer Biomark; 2018; 22(2):311-316. PubMed ID: 29660900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
